NF-κB and AP-1 regulate activation-dependent CD137 (4-1BB) expression in T cells

被引:46
|
作者
Kim, JO
Kim, HW
Baek, KM
Kang, CY [1 ]
机构
[1] Seoul Natl Univ, Coll Pharm, Immunol Lab, Seoul 151742, South Korea
[2] Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul 151742, South Korea
关键词
4-1BB; CD137; T cell activation; T cell receptor signal; transcription factor;
D O I
10.1016/S0014-5793(03)00326-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
4-1BB(CD137) is a member of the tumor necrosis factor receptor superfamily and provides a costimulatory signal by interaction with 4-1BB ligand expressed on antigen-presenting cells. The expression of 4-1BB is known to be activation-dependent. Here, we investigated the transcriptional machinery required for T cell receptor (TCR) activation-dependent induction of 4-1BB expression in CD3-CEM cells treated with phorbol myristate acetate and ionomycin. Using 5'-deletion constructs of 4-1BB promoter in luciferase reporter assays, we demonstrated that the transcriptional elements mediating 4-1BB upregulation were located in the region between similar to 0.9 and similar to 1.1 kb from the translational start site. Characterization of these sites by electrophoretic mobility shift assay and site-directed mutagenesis revealed that nuclear factor kappaB (NF-kappaB) and activating protein-1 (AP-1) are involved. MEK and c-Jun N-terminal kinase-1 activity was required for activation-dependent 4-1BB upregulation. Thus, NF-kappaB and AP-1 are involved in the TCR stimulation-dependent transcriptional regulation of the 4-1BB promoter. (C) 2003 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:163 / 170
页数:8
相关论文
共 50 条
  • [41] Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
    Liu, Guizhong
    Luo, Peter
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
    Claus, Christina
    Ferrara-Koller, Claudia
    Klein, Christian
    MABS, 2023, 15 (01)
  • [43] Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies
    Melero, Ignacio
    Murillo, Oihana
    Dubrot, Juan
    Hervas-Stubbs, Sandra
    Perez-Gracia, Jose L.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (08) : 383 - 390
  • [44] 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
    Vinay, Dass S.
    Kwon, Byoung S.
    BMB REPORTS, 2014, 47 (03) : 122 - 129
  • [45] IκB Kinase β Is Required for Activation of NF-κB and AP-1 in CD3/CD28-Stimulated Primary CD4+ T Cells
    Lupino, Elisa
    Ramondetti, Cristina
    Piccinini, Marco
    JOURNAL OF IMMUNOLOGY, 2012, 188 (06): : 2545 - 2555
  • [46] Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
    Zhao, Yuan
    Tahiliani, Vikas
    Salek-Ardakani, Shahram
    Croft, Michael
    FRONTIERS IN IMMUNOLOGY, 2012, 3
  • [47] New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
    Etxeberria, Inaki
    Glez-Vaz, Javier
    Teijeira, Alvaro
    Melero, Ignacio
    ESMO OPEN, 2019, 4 : e000733
  • [48] NF-KB and AP-1 connection:: Mechanism of NF-κB-Dependent regulation of AP-1 activity
    Fujioka, S
    Niu, JG
    Schmidt, C
    Sclabas, GA
    Peng, BL
    Uwagawa, T
    Li, ZK
    Evans, DB
    Abbruzzese, JL
    Chiao, PJ
    MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (17) : 7806 - 7819
  • [49] Human monocytes display different levels of CD137/4-1BB expression linked to certain immunometabolic features
    Stoll, A.
    Bruns, H.
    Saul, D.
    Mackensen, A.
    Mougiakakos, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 136 - 136
  • [50] Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137)
    Bansal-Pakala, P
    Croft, M
    JOURNAL OF IMMUNOLOGY, 2002, 169 (09): : 5005 - 5009